Science Advances

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, April 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Friday, March 15, 2024
Libin Cardiovascular Institute, Kidney, User experience, Assistant, AKI, Patient, Kidney disease, Inflammation, Hospital, TMX Group, Acute kidney injury, University, Ischemia, Injury, Dispute board, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Division, Phase, OTCQB, Liver, Yolo Bypass, Randomness, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • “We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .

The ECB’s climate and nature plan 2024-2025

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, SAFE, Communication, Temperature, Employment, Climate change, Growth, United Nations Environment Programme, Green, Environment, ECB, European Parliament, Agriculture, Blog, Risk, Green Deal, Climate, United Nations, Research, Policy, Food, Disclosure, Nature, Carbon, Flood, Commission, Biodiversity loss, Council, Science Advances, European, Investment, Tourism, Deutsche Bundesbank, Heart, Ecosystem, European Commission, Soil, Nickel, The Green Deal, European Environment Agency, Weather, Renewable energy

Climate change is increasingly affecting the euro area economy. That is why the ECB is committed to integrating climate change considerations into its activities. On 30 January 2024 the ECB published its climate and nature plan 2024-2025, which identifies three focus areas for its future work: (i) navigating the transition towards a green economy

Key Points: 


Climate change is increasingly affecting the euro area economy. That is why the ECB is committed to integrating climate change considerations into its activities. On 30 January 2024 the ECB published its climate and nature plan 2024-2025, which identifies three focus areas for its future work: (i) navigating the transition towards a green economy

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Thursday, March 7, 2024
Oxygen, Liver, OTCQB, CABG, User experience, Injury, Science Advances, Inflammation, Randomness, Hospital, Kidney disease, Acute kidney injury, National Research Council, TMX Group, Kidney, Yolo Bypass, IRI, Risk, Placebo-controlled study, Reperfusion, Prevalence, Arch, Ischemia, Disease, Patient, AKI, Phase, Mortality, Erciyes University, Faculty, Pharmaceutical industry

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Arch Biopartners team is currently working with hospital sites in Canada to prepare for their participation in this Phase II trial.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Tuesday, March 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 10, 2024
Mortality, Arch, Kidney, Patient, TMX Group, Ischemia, Reperfusion, Kidney disease, Oxygen, Yolo Bypass, Letter, Science Advances, AKI, Injury, Risk, CABG, OTCQB, Disease, Food, National Research Council, IRI, Acute kidney injury, Liver, Inflammation, Phase, Health Canada, Prevalence, Pharmaceutical industry

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 3, 2024
Liver, Arch, AKI, Risk, Reperfusion, IRI, Prevalence, Disease, Mortality, TMX Group, Science Advances, Inflammation, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, Ministry, Health Canada, Kidney, Injury, Patient, Ischemia, MOH, Pharmaceutical industry

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
  • Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Thursday, December 21, 2023
Clinical trial, Liver, Arch, AKI, Conlon, Reperfusion, Risk, IRI, Prevalence, Ethics, Disease, Mortality, TMX Group, Science Advances, Cardiopulmonary bypass, Inflammation, CPB, Renal replacement therapy, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, MOH, Health Canada, Kidney, Injury, Patient, Ischemia, Dialysis, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
  • Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Wednesday, December 13, 2023
Clinical trial, Phase, Liver, Arch, Food, AKI, Conlon, Reperfusion, Risk, IRI, FDA, Prevalence, Disease, Mortality, TMX Group, Science Advances, Cardiopulmonary bypass, Inflammation, Investigational New Drug, CPB, Renal replacement therapy, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, Health Canada, Kidney, Patient, Safety, Ischemia, Dialysis, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The FDA granted the Company permission to proceed with a Phase II trial in late June .
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “The clinical trial application submitted to Health Canada is the result of clinical interest in Canada to support our Phase II trial targeting CS-AKI.
  • LSALT peptide has been shown to prevent ischemia reperfusion injury (IRI) to the kidneys in pre-clinical models , providing the scientific rationale for Arch to use LSALT peptide in this CS-AKI trial.

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

Retrieved on: 
Thursday, November 23, 2023
Lung, Hypotension, ODD, Tissue, Clinical trial, Protein, Mortality, Mouse, Edema, Therapy, Blood, Systemic, NIH, Survival, Histamine, Hypertelorism, KOSDAQ, Pharmaceutical industry, Vaccine, TEK tyrosine kinase, Science Advances, Hypoalbuminemia

Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.

Key Points: 
  • Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.
  • The results underscore the novel mechanism of action, demonstrating the ability of PMC-403 to reduce vascular leakage associated with ISCLS in the preclinical models.
  • In February 2023, the US FDA granted Orphan Drug Designation (ODD) for PMC-403 for the treatment of Systemic Capillary Leak Syndrome.
  • Dr. Kirk Druey's team shared enthusiasm for the potential breakthrough, underscoring their strong determination to advance into clinical trial.